Doris Apt

1.1k total citations
20 papers, 866 citations indexed

About

Doris Apt is a scholar working on Molecular Biology, Epidemiology and Genetics. According to data from OpenAlex, Doris Apt has authored 20 papers receiving a total of 866 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 6 papers in Epidemiology and 6 papers in Genetics. Recurrent topics in Doris Apt's work include Virus-based gene therapy research (4 papers), Cancer Treatment and Pharmacology (4 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Doris Apt is often cited by papers focused on Virus-based gene therapy research (4 papers), Cancer Treatment and Pharmacology (4 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Doris Apt collaborates with scholars based in United States, Singapore and Germany. Doris Apt's co-authors include Hans‐Ulrich Bernard, T Chong, Yichun Liu, Guntram Suske, Bernd Gloss, Muhammad Isa, Yi Liu, Juha Punnonen, Kanakatte Raviprakash and Craig Skinner and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Doris Apt

20 papers receiving 851 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Doris Apt United States	11	450	249	189	123	120	20	866
Qingfu Xu United States	23	430 1.0×	563 2.3×	84 0.4×	91 0.7×	91 0.8×	58	1.2k
Agata Levay United States	16	751 1.7×	292 1.2×	161 0.9×	428 3.5×	156 1.3×	21	1.4k
Daniel C. Edelman United States	17	393 0.9×	133 0.5×	213 1.1×	53 0.4×	75 0.6×	34	903
Stacia Phillips United States	12	312 0.7×	263 1.1×	128 0.7×	106 0.9×	66 0.6×	27	711
William H. Schubach United States	21	781 1.7×	156 0.6×	325 1.7×	244 2.0×	220 1.8×	34	1.4k
Guigao Lin China	17	688 1.5×	177 0.7×	100 0.5×	61 0.5×	135 1.1×	71	1.2k
Pia V. Kasperkovitz United States	13	345 0.8×	189 0.8×	189 1.0×	287 2.3×	32 0.3×	13	946
Rafael Núñez United States	14	291 0.6×	80 0.3×	124 0.7×	243 2.0×	65 0.5×	40	748
Paola Sette United States	14	283 0.6×	183 0.7×	111 0.6×	224 1.8×	75 0.6×	25	712
Shivkumar Venkatasubrahmanyam United States	12	1.4k 3.1×	115 0.5×	142 0.8×	277 2.3×	110 0.9×	16	1.9k

Countries citing papers authored by Doris Apt

Since Specialization

Citations

This map shows the geographic impact of Doris Apt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Doris Apt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Doris Apt more than expected).

Fields of papers citing papers by Doris Apt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Doris Apt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Doris Apt. The network helps show where Doris Apt may publish in the future.

Co-authorship network of co-authors of Doris Apt

This figure shows the co-authorship network connecting the top 25 collaborators of Doris Apt. A scholar is included among the top collaborators of Doris Apt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Doris Apt. Doris Apt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Dolly, Saoirse, Andrew J. Wagner, Johanna C. Bendell, et al.. (2016). Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(12). 2874–2884. 105 indexed citations

2.

Vuylsteke, Peter, Manon Huizing, Katarína Petráková, et al.. (2016). Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study. Annals of Oncology. 27(11). 2059–2066. 91 indexed citations

3.

Vuylsteke, Peter, Katarína Petráková, Rebecca Roylance, et al.. (2015). 1803 PEGGY: A phase II randomised study of the PI3-kinase (PI3K) inhibitor pictilisib (GDC-0941) plus paclitaxel in patients (pts) with hormone receptor (HR)-positive, HER2-negative locally recurrent or metastatic breast cancer (mBC). European Journal of Cancer. 51. S265–S266. 2 indexed citations

4.

Schöffski, Patrick, Sara Cresta, Ingrid A. Mayer, et al.. (2015). Abstract P5-19-10: Tolerability and anti-tumor activity of the oral PI3K inhibitor GDC-0941 in combination with paclitaxel, with and without bevacizumab or trastuzumab in patients with locally recurrent or metastatic breast cancer. Cancer Research. 75(9_Supplement). P5–19. 3 indexed citations

5.

Scholz, Markus, et al.. (2009). Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony‐stimulating factor derivative Maxy‐G34 and pegfilgrastim in rats. Cell Proliferation. 42(6). 823–837. 14 indexed citations

6.

Schwartzberg, L., et al.. (2009). An open-label, dose-escalating study of Maxy-G34, a novel potent, long-acting Pegylated G-CSF, compared with pegfilgrastim (PF) for the treatment of chemotherapy induced neutropenia (CIN). Journal of Clinical Oncology. 27(15_suppl). e14500–e14500. 3 indexed citations

7.

Neighbors, Margaret, et al.. (2008). EpCAM-specific Vaccine Response by Modified Antigen and Chimeric Costimulatory Molecule in Cynomolgus Monkeys. Journal of Immunotherapy. 31(7). 644–655. 7 indexed citations

8.

Raviprakash, Kanakatte, Doris Apt, Craig Skinner, et al.. (2006). A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques. Virology. 353(1). 166–173. 54 indexed citations

9.

Apt, Doris, Kanakatte Raviprakash, Shumin Yang, et al.. (2005). Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen. Vaccine. 24(3). 335–344. 74 indexed citations

10.

Wright, Anne, Glenn Dawes, Andreas Crameri, et al.. (2005). Diverse Plasmid DNA Vectors by Directed Molecular Evolution of Cytomegalovirus Promoters. Human Gene Therapy. 16(7). 881–892. 20 indexed citations

11.

Locher, Christopher P., Volker Heinrichs, Doris Apt, & Robert G. Whalen. (2004). Overcoming antigenic diversity and improving vaccines using DNA shuffling and screening technologies. Expert Opinion on Biological Therapy. 4(4). 589–597. 7 indexed citations

12.

Locher, Christopher P., Volker Heinrichs, Doris Apt, & Robert G. Whalen. (2004). Overcoming antigenic diversity and improving vaccines using DNA shuffling and screening technologies. Expert Opinion on Biological Therapy. 4(4). 589–597. 1 indexed citations

13.

Locher, Christopher P., Volker Heinrichs, Doris Apt, & Robert G. Whalen. (2004). Overcoming antigenic diversity and improving vaccines using DNA shuffling and screening technologies. Expert Opinion on Biological Therapy. 4(4). 589–597. 1 indexed citations

14.

Liu, Yichun, Hans‐Ulrich Bernard, & Doris Apt. (1997). NFI-B3, a Novel Transcriptional Repressor of the Nuclear Factor I Family, Is Generated by Alternative RNA Processing. Journal of Biological Chemistry. 272(16). 10739–10745. 49 indexed citations

15.

Apt, Doris, et al.. (1996). High Sp1/Sp3 Ratios in Epithelial Cells during Epithelial Differentiation and Cellular Transformation Correlate with the Activation of the HPV-16 Promoter. Virology. 224(1). 281–291. 140 indexed citations

16.

Apt, Doris, Yichun Liu, & Hans‐Ulrich Bernard. (1994). Cloning and functional analysis of spliced isoforms of human nuclear factor I-X: interference with transcriptional activation by NFI/CTF in a cell-type specific manner. Nucleic Acids Research. 22(19). 3825–3833. 70 indexed citations

17.

Apt, Doris, T Chong, Yi Liu, & Hans‐Ulrich Bernard. (1993). Nuclear factor I and epithelial cell-specific transcription of human papillomavirus type 16. Journal of Virology. 67(8). 4455–4463. 86 indexed citations

18.

Chong, T, Doris Apt, Bernd Gloss, Muhammad Isa, & Hans‐Ulrich Bernard. (1991). The enhancer of human papillomavirus type 16: binding sites for the ubiquitous transcription factors oct-1, NFA, TEF-2, NF1, and AP-1 participate in epithelial cell-specific transcription. Journal of Virology. 65(11). 5933–5943. 130 indexed citations

19.

Apt, Doris, et al.. (1989). Endogenous retroviral env genes after N-methyl-N'-nitro-N-nitrosoguanidine treatment of mouse tumor cells: stable DNA amplification and rearrangement.. PubMed. 49(14). 3966–71. 4 indexed citations

20.

Altevogt, Peter & Doris Apt. (1988). High-frequency generation of altered Mr 70,000 env glycoproteins in N-methyl-N'-nitro-N-nitrosoguanidine-treated murine tumor cells.. PubMed. 48(5). 1137–42. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact